Say It With Technology: How Alnylam Fosters A Connected Relationship With Sites
Source: IQVIA Technologies
Alnylam Pharmaceuticals is developing an entirely new class of medicines and delivered the world’s first and only approved RNAi therapeutics in 2018 and 2019. Learn how Alnylam earned its reputation among investigators as a sponsor of choice by standardizing studies on a collaborative portal more than 6 years ago and leveraging technology to deliver:
- Informative, engaging, and inspirational communities for sites
- Digital study management that minimizes administrative burden
- Learning management that helps every site succeed, even first-time investigators
- Protocol-specific solutions that facilitate pre-screening scenarios, guide complicated visit scheduling, and protect patients
Speakers
- James (Jimmy) Keegan, Clinical Trial Specialist, Alnylam Pharmaceuticals
- Saraba Kuchibhotla, MPH, Clinical Trial Specialist, Alnylam Pharmaceuticals
- Tennyson Hunt, Clinical Trial Specialist, Alnylam Pharmaceuticals
- Lesley Freese, Assoc. Director, Trial Operations, IQVIA Technologies
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
IQVIA Technologies
This website uses cookies to ensure you get the best experience on our website. Learn more